← Amphastar Pharmaceuticals, Inc. (AMPH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Amphastar Pharmaceuticals, Inc. (AMPH)
Pharmaceutical Preparations · market cap $1.0B · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
15
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Amphastar Pharmaceuticals (AMPH) is a specialty pharma company focused on inhalation and intranasal products, with a market cap of ~$871M and ~$721M in trailing revenue. Its lead pipeline asset is an epinephrine inhalation aerosol in Phase 3 for asthma, alongside a broader pipeline of inhaled drug formulations at various stages. The company carries net debt of ~$440.5M against $170.9M in cash, with consistent but declining profitability over the past two years.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Epinephrine inhalation aerosol | Phase 3 | Asthma |
| I004 | Phase 3 | Pharmacokinetics |
| A006 DPI | Phase 2 | Asthma |
| Epinephrine Inhalation Aerosol, HFA | Phase 2 | Asthma |
| E004 (Epinephrine Inhalation Aerosol) HFA-MDI | Phase 3 | Asthma |
| Proventil® MDI | Phase 2 | Asthma |
| A006 | Phase 2 | Asthma |
| Arm T1: Primatene Mist HFA | Phase 2 | Asthma |
| Epinephrine HFA-MDI (E004) | Phase 3 | Asthma |
| Hyaluronidase | Phase 2 | Allergic Skin Reaction |
| Primatene Mist | Phase 3 | Asthma |
| Epinephrine inhalation | Phase 3 | Asthma |
| NovoLog | Phase 3 | Pharmacokinetics |
| albuterol inhalation powder | Phase 2 | Asthma |
| Albuterol DPI 25 mcg/inh | Phase 2 | Asthma |
Price & technical context
3-month
+29.1%
6-month
+25.2%
12-month
-4.9%
52-wk range
$16.87–$29.40
vs 50-day MA
+13.5%
vs 200-day MA
+13.4%
Realized vol
54.3%
Max drawdown
-68.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AMPH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.